Open Access<p>Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World</p>
Author(s) -
Le Zhang,
Fangfang Chen,
Shikai Geng,
Xiaodong Wang,
Liyang Gu,
Yitian Lang,
Ting Li,
Shuang Ye
Publication year - 2020
Publication title -
journal of inflammation research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.656
H-Index - 33
ISSN - 1178-7031
DOI - 10.2147/jir.s282249
Subject(s) - hydroxychloroquine , rheumatoid arthritis , leflunomide , methotrexate , medicine , cohort , arthritis , antifolate , gastroenterology , antimetabolite , disease , covid-19 , infectious disease (medical specialty)
To compare the efficacy, safety, and cost-effectiveness of methotrexate (MTX) plus hydroxychloroquine (HCQ) vs MTX plus leflunomide (LEF) in established rheumatoid arthritis (RA) with inadequate response to MTX monotherapy in a real-world Chinese cohort.